BioNTech's cancer pipeline is bigger than its COVID-era reputation suggests, and the stock still trades below $100.

The company is looking to prove it can achieve significant success outside the coronavirus market.

Pfizer Canada and BioNTech announced Health Canada’s approval of the Omicron XFG‑adapted COMIRNATY vaccine for individuals ...

Both have attracted considerable attention from Wall Street recently.

Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has ...

Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term ...

BioNTech’s oncology strategy centers on a bispecific antibody that the company envisions as the backbone of many potential drug combinations for many types of cancer. Bristol Myer Squibb is buying ...

BioNTech closed at EUR 83.80, down 2.6%, as shrinking Comirnaty sales and a BMO downgrade offset promising Gotistobart cancer data.

BioNTech's Oncology Pivot Faces Its First Real Test in Madrid Illustration mit AI erstellt.

Bristol Myers Squibb (BMS) has agreed to co-develop and co-commercialize BioNTech’s cancer-fighting bispecific antibody candidate BNT327 across numerous solid tumor types through a collaboration that ...

BMO Capital Markets downgraded BioNTech and lowered its price target for the stock. The move came after BioNTech reduced its 2027 guidance and experienced a clinical setback. However, BioNTech's ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...